These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1866 related items for PubMed ID: 17476007

  • 1. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial.
    N Engl J Med; 2007 May 03; 356(18):1809-22. PubMed ID: 17476007
    [Abstract] [Full Text] [Related]

  • 2. [Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].
    Geusens PP, Lems WF.
    Ned Tijdschr Geneeskd; 2007 Jun 30; 151(26):1445-8. PubMed ID: 17633971
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
    Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P, Haentjens P, Lyles KW.
    J Am Geriatr Soc; 2010 Feb 30; 58(2):292-9. PubMed ID: 20070415
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
    Nakamura T, Fukunaga M, Nakano T, Kishimoto H, Ito M, Hagino H, Sone T, Taguchi A, Tanaka S, Ohashi M, Ota Y, Shiraki M.
    Osteoporos Int; 2017 Jan 30; 28(1):389-398. PubMed ID: 27631091
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial.
    N Engl J Med; 2009 Aug 20; 361(8):756-65. PubMed ID: 19671655
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.
    Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T.
    Osteoporos Int; 2009 Aug 20; 20(8):1429-37. PubMed ID: 19101754
    [Abstract] [Full Text] [Related]

  • 15. Zoledronic acid: a review of its use in the treatment of osteoporosis.
    Deeks ED, Perry CM.
    Drugs Aging; 2008 Aug 20; 25(11):963-86. PubMed ID: 18947264
    [Abstract] [Full Text] [Related]

  • 16. [Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].
    Dalle Carbonare L, Bertoldo F, Lo Cascio V.
    Reumatismo; 2009 Aug 20; 61(1):54-64. PubMed ID: 19370189
    [Abstract] [Full Text] [Related]

  • 17. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar 20; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 18. The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis.
    Hwang JS, Chin LS, Chen JF, Yang TS, Chen PQ, Tsai KS, Leung PC.
    J Bone Miner Metab; 2011 May 20; 29(3):328-33. PubMed ID: 20922438
    [Abstract] [Full Text] [Related]

  • 19. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 20; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 20. Once-yearly zoledronic acid in older men compared with women with recent hip fracture.
    Boonen S, Orwoll E, Magaziner J, Colón-Emeric CS, Adachi JD, Bucci-Rechtweg C, Haentjens P, Kaufman JM, Rizzoli R, Vanderschueren D, Claessens F, Sermon A, Witvrouw R, Milisen K, Su G, Lyles KW, HORIZON Recurrent Fracture Trial.
    J Am Geriatr Soc; 2011 Nov 20; 59(11):2084-90. PubMed ID: 22091563
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 94.